Comparative Pharmacology
Head-to-head clinical analysis: AUREOMYCIN versus OXYTETRACYCLINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUREOMYCIN versus OXYTETRACYCLINE HYDROCHLORIDE.
AUREOMYCIN vs OXYTETRACYCLINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 30S ribosomal subunit, inhibiting protein synthesis by blocking aminoacyl-tRNA binding.
Oxytetracycline binds reversibly to the 30S ribosomal subunit, inhibiting protein synthesis by blocking the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
250-500 mg orally every 6 hours; or 10-20 mg/kg/day intravenously divided every 12 hours
250-500 mg orally every 6 hours or 1-2 g/day divided every 12 hours intravenously.
None Documented
None Documented
Terminal elimination half-life: 8–12 hours (prolonged in renal impairment; may extend to 20–30 hours in anuria)
6-10 hours (prolonged to 48-100 hours in renal impairment; consider dose adjustment in CrCl <50 mL/min)
Renal (70% unchanged), biliary/fecal (30% as metabolites and unchanged drug)
Renal (60-70% unchanged by glomerular filtration); biliary/fecal (20-35%)
Category C
Category D/X
Tetracycline Antibiotic
Tetracycline Antibiotic